QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
How did QGEN's recent EPS compare to expectations?
The most recent EPS for Qiagen NV is $0.54, not beating expectations of $0.55.
How did Qiagen NV QGEN's revenue perform in the last quarter?
Qiagen NV revenue for the last quarter is $0.54
What is the revenue estimate for Qiagen NV?
According to 10 of Wall street analyst, the revenue estimate of Qiagen NV range from $560.07M to $516.16M
What's the earning quality score for Qiagen NV?
Qiagen NV has a earning quality score of A-/64.85506. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does Qiagen NV report earnings?
Qiagen NV next earnings report is expected in 2026-08-04
What are Qiagen NV's expected earnings?
Qiagen NV expected earnings is $507.19M, according to wall-street analysts.
Did Qiagen NV beat earnings expectations?
Qiagen NV recent earnings of $492.0M does not beat expectations.